继发性红细胞增多症的血栓形成风险类似于低危真性红细胞增多症，且在特定患者亚组中增加。 - Suppr

Thrombotic risk in secondary polycythemia resembles low-risk polycythemia vera and increases in specific subsets of patients.

作者信息

Krečak Ivan, Holik Hrvoje, Zekanović Ivan, Morić Perić Martina, Marketin Tina, Coha Božena, Gverić-Krečak Velka, Vodanović Marijo, Lucijanić Marko

机构信息

Department of Internal Medicine, General Hospital of Šibenik-Knin County, Šibenik, Croatia.

Department of Internal Medicine, "Dr. Josip Benčević" General Hospital, Slavonski Brod, Croatia; School of Medicine, University of Osijek, Osijek, Croatia.

出版信息

Thromb Res. 2022 Jan;209:47-50. doi: 10.1016/j.thromres.2021.11.025. Epub 2021 Dec 1.

DOI:10.1016/j.thromres.2021.11.025

PMID:34864474

Abstract

摘要

相似文献

Thrombotic risk in secondary polycythemia resembles low-risk polycythemia vera and increases in specific subsets of patients.继发性红细胞增多症的血栓形成风险类似于低危真性红细胞增多症，且在特定患者亚组中增加。

Thromb Res. 2022 Jan;209:47-50. doi: 10.1016/j.thromres.2021.11.025. Epub 2021 Dec 1.

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].[JAK2V617F突变在慢性骨髓增殖性肿瘤患者中的意义]

Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226.

Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.真性红细胞增多症、原发性血小板增多症以及原发性骨髓纤维化伴或不伴JAK2 V617F突变时的巨核细胞形态及临床参数

Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.

The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia.因子 V 莱顿、凝血酶原 G20210A 和 MTHFR 突变与真性红细胞增多症和原发性血小板增多症中首次主要血栓事件的关系。

Ann Hematol. 2014 Feb;93(2):203-9. doi: 10.1007/s00277-013-1838-6. Epub 2013 Jul 5.

JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.真性红细胞增多症或特发性红细胞增多症中的JAK2外显子12突变。

Haematologica. 2007 Dec;92(12):1717-8. doi: 10.3324/haematol.12011.

Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.根据JAK2 V617F突变状态，原发性血小板增多症和真性红细胞增多症患者的血栓形成风险。

Haematologica. 2007 Jan;92(1):135-6. doi: 10.3324/haematol.10634.

Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.真性红细胞增多症中不受控制的血小板增多症是血栓形成的危险因素，无论JAK2（V617F）突变状态如何。

Leukemia. 2007 Dec;21(12):2544-5. doi: 10.1038/sj.leu.2404829. Epub 2007 Jul 5.

Thrombosis among 1537 patients with JAK2 -mutated myeloproliferative neoplasms: Risk factors and development of a predictive model.1537 例 JAK2 突变骨髓增殖性肿瘤患者的血栓形成：危险因素和预测模型的建立。

Cancer Med. 2020 Mar;9(6):2096-2105. doi: 10.1002/cam4.2886. Epub 2020 Jan 28.

The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.JAK2 V617F突变、自发性红细胞生成和巨核细胞生成、高敏血小板、活化白细胞以及内皮细胞在真性红细胞增多症和原发性血小板增多症血栓形成表现病因中的作用。

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):381-98. doi: 10.1055/s-2006-942759.

The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.JAK2 V617F时代真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化的诊断与管理

Clin Adv Hematol Oncol. 2009 May;7(5):334-42.

引用本文的文献

Preoperative polycythemia may be associated with inferior postoperative outcomes: a retrospective study.术前红细胞增多症可能与较差的术后结局相关：一项回顾性研究。

Croat Med J. 2025 Jul 5;66(3):186-193.

Diagnostic Performance of Serum Erythropoietin to Discriminate Polycythemia Vera from Secondary Erythrocytosis through Established Subnormal Limits.通过既定的低于正常范围的血清促红细胞生成素鉴别真性红细胞增多症与继发性红细胞增多症的诊断效能

Diagnostics (Basel). 2024 Aug 29;14(17):1902. doi: 10.3390/diagnostics14171902.

The Systemic Inflammation Index: A New Candidate Minor Criterion in the Diagnosis of Polycythemia Vera.全身炎症指数：真性红细胞增多症诊断中一个新的候选次要标准

J Pers Med. 2024 Apr 29;14(5):471. doi: 10.3390/jpm14050471.

Diagnostic Approaches to Investigate JAK2-Unmutated Erythrocytosis Based on a Single Tertiary Center Experience.基于单一三级中心经验的JAK2未突变红细胞增多症的诊断方法

Mol Diagn Ther. 2024 May;28(3):311-318. doi: 10.1007/s40291-024-00703-3. Epub 2024 Apr 3.

Concomitant Cerebral Venous Thrombosis and Intracranial Hemorrhages in Presentation of a Patient with Secondary Polycythemia: A Case Report.继发红细胞增多症患者表现为同时合并脑静脉血栓形成和颅内出血：病例报告。

Am J Case Rep. 2023 Oct 15;24:e941507. doi: 10.12659/AJCR.941507.

Incidence, Risk Factors and Mortality Associated with Major Bleeding Events in Hospitalized COVID-19 Patients.住院COVID-19患者主要出血事件的发生率、危险因素及死亡率

Life (Basel). 2023 Aug 7;13(8):1699. doi: 10.3390/life13081699.

Secondary polycythaemia from chronic hypoxia is a risk for cerebral thrombosis: a case report.慢性缺氧继发红细胞增多症增加脑血栓风险：病例报告。

BMC Neurol. 2023 Jun 9;23(1):225. doi: 10.1186/s12883-023-03277-5.

JAK2 Unmutated Polycythaemia-Real-World Data of 10 Years from a Tertiary Reference Hospital.JAK2未突变型真性红细胞增多症——来自一家三级转诊医院的10年真实世界数据。

J Clin Med. 2022 Jun 13;11(12):3393. doi: 10.3390/jcm11123393.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Thrombotic risk in secondary polycythemia resembles low-risk polycythemia vera and increases in specific subsets of patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献